Eli Lilly Enters Nuclear Isotope Business To Back Cancer Treatment

Lilly Enters Nuclear Isotope Production for Cancer Drug Development

Partnership with Aktis Oncology

Eli Lilly and Company, the world's largest pharmaceutical group by market value, has announced a partnership with biotechnology company Aktis Oncology to develop radiopharmaceuticals for cancer. Under the terms of the deal, Eli Lilly will pay Aktis Oncology an upfront payment and milestones for the exclusive rights to develop, manufacture, and commercialize Aktis Oncology's lead radiopharmaceutical candidate.

Expansion into Radiopharmaceuticals

This partnership represents a significant expansion for Eli Lilly into the field of radiopharmaceuticals, which are drugs that use radioactive isotopes to target and destroy cancer cells. Eli Lilly has been actively pursuing this area in recent years, and the partnership with Aktis Oncology will accelerate its progress in developing new cancer treatments.

Acquisition of Radionetics Oncology

In a separate deal, Eli Lilly has also acquired Radionetics Oncology, a biotechnology company specializing in the discovery and development of radiopharmaceuticals. The acquisition gives Eli Lilly access to Radionetics Oncology's pipeline of radiopharmaceutical candidates and its expertise in this field.